Regeneron reported a 36% revenue increase to $5.1 billion in Q3 2026, with record sales for Dupixent, EYLEA HD, and Libtayo. GAAP EPS rose 35% to $18.45, and non-GAAP EPS jumped 70% to $20.07. The company expanded its collaboration with Sanofi, securing $1 billion upfront and potential $7 billion in milestones. FDA approved Pasatru for a rare bone disease, and multiple pipeline programs continue progressing, including upcoming FDA decisions and new clinical trials.
Regeneron Pharmaceuticals (REGN) shares trade at USD 838.87, close to their 52-week high of USD 852.03, showing a 2.45% gain as of Oct 30, 2026 17:11 WIB. In contrast, Sanofi (SNY) is priced at USD 44.70, also up 3.64% but further from its 52-week high of USD 52.34. Despite Sanofi's larger market cap of $101.77B compared to Regeneron's $84.30B, Regeneron's stock shows strong momentum on Pluang with a typical hold time of 108 days versus 95 days for Sanofi.
Regeneron will report its Q3 earnings on October 30, marking the first quarter it fully books its share of Dupixent profits from Sanofi after repaying a $3.1 billion development balance. This change is expected to significantly boost collaboration re...
Regeneron Pharmaceuticals has extended its agreement with the U.S. government's BARDA to supply additional doses of Inmazeb, an FDA-approved antibody treatment for Ebola caused by Orthoebolavirus zairense. The expanded deal, valued at approximately $...
